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BACKGROUND The aim of this trial was to compare healing (assessed
by optical coherence tomography-OCT) of biolimus A9 and everolimus
drug-eluting stents at 9-month follow-up in patients with ST-segment
elevation myocardial infarction (STEMI) treated by primary PCI
(pPCI). 9-month clinical and angiographic data were also compared in
both groups.
METHODS 201 patients with STEMI treated by primary PCI were
randomly enrolled in the trial. 101 patients were randomized to the
biolimus A9 stent group and 100 patients to the everolimus group. All
patients were pre-treated with a standard therapy (unfractionated
heparin, aspirin and clopidogrel). The use of inhibitors of GP IIb/IIIa
and thrombus-aspiration were left at the discretion of physicians,
however both were strongly recommended. Stent implantation was
carried out according to the standard clinical practice employing low
pressure stent deployment with high-pressure postdilatation using
shorter, non-compliant balloon. All patients were scheduled for 9-
month clinical, angiographic and OCT follow-up. Primary end-point of
this study were the number of uncovered struts.
RESULTS All procedures were carried out without complications in
both groups. Baseline demographic and procedural characteristic
were well balanced in both groups. The rate of MACE did not differ
signiﬁcantly at 30 days between both groups. There was one acute
stent thrombosis requiring immediate re-PCI in the everolimus stent
group and one asymptomatic stent thrombosis in the biolimus group
(revealed during stage PCI of non-culprit lesion). Furthermore, there
was one non-cardiac death in the biolimus group. 9-month angio-
graphic and OCT follow-up underwent 87% patients in everolimus
and 90% patients in biolimus group respectively. At 9-month follow,
the rate of MACE and angiographic restenosis were comparable and
very low in both groups (2 vs. 1% and 1 vs 1% respectively; P¼NS). All
in-segment and in-stent angiographic data (reference diameter, min-
imal diameter, mean diameter, % stenosis) were comparable at 9-
month in both groups. OCT data presents Table. The rate of uncovered
struts were signiﬁcantly higher in biolimus group (19.6716.52 vs.
9.9910.38; p¼0.0001). On the other hand, there was a trend to higher
mean and minimal lumen diameter (3.35mm0.56 vs. 3.2mm0.43;
p¼0.06 and 2.88mm0.55 vs. 2.74mm0.49; p¼0.09).
CONCLUSIONS At 9-month follow-up, second generation everolimus
drug-eluting stent shows better healing when compared to biolimus
second generation drug-eluting stent. However, the stent struts
coverage is considerably high in both groups.
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BACKGROUND The Biolimus A9 coated Biofreedom stent is a polymer
free stainless steel drug eluting stent. In an animal models 98% of the
drug has diffused into the vessel wall in 1 month and it is reasonable
to consider short term DAPT of 1 month for patients with this stent.
Moreover, Biofreedom stent would be ideal in patients who may not
tolerate 12 months of DAPT therapy. The aims of this study was to
evaluate the indications, safety, efﬁcacy and medium term outcome
of real world patients who had PCI using Biofreedom stent and short
term DAPT therapy.METHODS The cardiac interventional center at the Royal Bourne-
mouth Hospital, UK has been one of the leading recruiting centers in
the world for the Biofreedom stent LEADERS Free trial. After the
recruitment period was complete, open label Biofreedom stent was
incorporated in selected PCI cases who had high risk of bleeding and
would beneﬁt from short term DAPT therapy. The indication for PCI,
procedural details, images, equipment used, complications and follow
up details were recorded and analyzed.
RESULTS From August 2014 - May 2015, 1690 stent cases were iden-
tiﬁed of which Biofreedom stent was used in 60 cases (3.6%). Mean
age of these 60 was 76.6þ/-10.5 years, 41 (68%) were males. The
indication for PCI was STEMI 4 (6.7%), Non-STEMI 18 (30%), unstable
angina 5 (8.3%), stable angina 21 (35%) and staged procedure in 12
(20%) patients. Left ventricular systolic function was normal in 56.6%,
mildly impaired 6.6%, moderately impaired 21.6% and severely
impaired in 6.6%. A Biofreedom stent was selected during PCI in view
of concomitant warfarin therapy in 27 (56.5%), elderly age 9 (15%),
awaiting noncardiac surgery 8 (13.3%), anemia 3 (5%), bleeding issues
9 (15%) and due to poor compliance of medication in 4 (6.6%). Stent
was deployed in LMS in 2, LAD 34, circumﬂex 17, RCA in 12 and 2 in
venous graft. The lesion was predilated in 48 (80%) of cases and
rotablation and laser atherectomy was performed prior to stent
deployment in 8 (13.3%) and 3 (5%), respectively. The mean stent
diameter was 3.08þ/-0.40mm and length 35.8þ/-18.8mm. No major
complications was recorded during the stent deployment 1 month
DAPT therapy was advised in 55 (91.6%), 6 months in 1 and 12 months
in 4 patients. Patients were followed up for a period of 160þ/-84 days.
Fifty three (88%) had a good medium term outcome. Five (8.3%) died
during the follow up period (4 patients with either cardiogenic shock,
ventilated primary PCI and VT). One patient each developed reste-
nosis and subacute stent thrombosis (Biofreedom deployed after laser
PCI for underexpanded stent).
CONCLUSIONS The use of very short term DAPT with the Biofreedom
stent in patients at high risk of bleeding events was associated with
event free survival of 88% within this small case series. When
prolonged DAPT is contraindicated, Biofreedom offers an alternative
solution to conventional DES and
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BACKGROUND Inﬂammation is well known as predictor of survival
among patients with chronic kidney disease (CKD), and the CKD was
reported as predictor of drug eluting stent (DES) stent failure.
Assessment of inﬂammation may be helpful to understand mecha-
nism of DES failure among CKD patients.
METHODS We investigated consecutive 1238 patients who have
available paired C-reactive protein (CRP) (pre-procedure as baseline
and 8-12 months later PCI as late-phase) among patients undergoing
DES implantation. CRP elevation was deﬁned as >0.2mg/dl. We
divided them into 5 groups according to CKD grade (G1-2: eGFR
>60ml/min; n¼673, G3a:45-59 ml/min; n¼308, G3b: 30-44 ml/min;
n¼118, G4: 29-15 ml/min; n¼34, G5: <15ml/min; n¼105), and investi-
gated occurrence of major adverse cardiac event (MACE) comprised
from all cause death, non-fetal myocardial infarction, target vessel
revascularization, and any other unplanned revascularization.
RESULTS Prevalence of CRP elevation at baseline was increased with
advance of CKD grade (G1-2; 35.0%, G3a; 32.5%, G3b; 39.0%, G4;
51.4%, and G5; 65.4%), and that was not decreased among patients
with CKD G4 and G5 at late phase (vs. baseline; 18.8%: P<0.0001,
20.8%: P¼0.0002, 21.2%: P¼0.003, 34.3%: P¼0.12, and 60.6%:
P¼0.58). Survival analysis revealed that MACE was frequently
occurred in CKD G5 than the other (Figure), and multivariate analysis
revealed that elevated late-phase CRP (HR;3.24, 95%CI; 2.46-4.26,
P<0.0001), number of diseased segment (HR;1.14, 95%CI; 1.07-1.20,
P<0.0001), diabetes mellitus (HR;1.41, 95%CI;1.08-1.83, P¼0.01), and
CKD G5 (HR;3.15, 95%CI;2.25-4.41, P<0.0001) was positive predictor of
occurrence of MACE, while statin was negative predictor (HR;0.75,
95%CI; 0.56-0.99, P¼0.048). Propensity score-matched analysis also
conﬁrmed effect of late-phase CRP elevation on MACE (HR: 3.50, 95%
CI: 2.63-4.65, P<0.0001).
